Baillie Gifford & Co’s Guardant Health GH Stock Holding History

Baillie Gifford & Co’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$343M	Sell	2,284,127 -1,574,919	-41%	-$171M	0.31%	67
2026 Q1	$356M	Sell	3,859,046 -1,030,980	-21%	-$104M	0.36%	58
2025 Q4	$499M	Sell	4,890,026 -237,666	-5%	-$21.3M	0.42%	49
2025 Q3	$320M	Buy	5,127,692 +317,906	+7%	+$17.3M	0.24%	78
2025 Q2	$250M	Sell	4,809,786 -251,225	-5%	-$11.2M	0.19%	84
2025 Q1	$216M	Sell	5,061,011 -388,089	-7%	-$16.7M	0.19%	86
2024 Q4	$166M	Sell	5,449,100 -422,924	-7%	-$11.9M	0.13%	111
2024 Q3	$135M	Sell	5,872,024 -221,262	-4%	-$6.26M	0.1%	113
2024 Q2	$176M	Sell	6,093,286 -138,818	-2%	-$3.23M	0.14%	102
2024 Q1	$129M	Buy	6,232,104 +53,292	+0.9%	+$1.14M	0.1%	112
2023 Q4	$167M	Buy	+6,178,812	New	+$162M	0.13%	106

Other funds holding GH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Baillie Gifford & Co's GH Position: Q2 2026 in Review

Baillie Gifford & Co reduced its Guardant Health (GH) stake by 41% in Q2 2026, selling an estimated $171M and leaving 2,284,127 shares worth $343M. The position accounts for 0.31% of the portfolio, ranked #67.

Baillie Gifford & Co first reported a position in GH in Q4 2023 and has held it in 11 quarters since. The position peaked at $499M in Q4 2025. 597 funds tracked by Wall St. Rank hold GH as of Q2 2026.

Baillie Gifford & Co held 2,284,127 shares of Guardant Health worth $343M as of Q2 2026.
Baillie Gifford & Co sold 1,574,919 Guardant Health shares in Q2 2026, an estimated $171M.
Guardant Health made up 0.31% of Baillie Gifford & Co's portfolio in Q2 2026, its #67 holding.
Baillie Gifford & Co first reported a position in Guardant Health in Q4 2023 and has held it in 11 quarters since.
Baillie Gifford & Co's Guardant Health position peaked at $499M in Q4 2025.
597 funds tracked by Wall St. Rank held Guardant Health as of Q2 2026.

Based on Baillie Gifford & Co's 13F filing for Q2 2026, filed 6 Aug 2026.